Entrada Therapeutics (TRDA) EBT Margin (2023 - 2026)

Entrada Therapeutics' EBT Margin history runs 4 years deep, the most recent figure standing at 4534.74% for Q1 2026.

• In Q1 2026, EBT Margin fell 445035.0% year-over-year to 4534.74%; the TTM figure through Mar 2026 stood at 2878.29% (down 289211.0% YoY), while the FY2025 annual figure was 561.84%, down 59338.0% from the prior year.
• EBT Margin was 4534.74% for Q1 2026 at Entrada Therapeutics, down from 3007.85% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 61.03% in Q2 2024 to a low of 4534.74% in Q1 2026.
• Historically, EBT Margin has averaged 962.84% across 4 years, with a median of 66.49% in 2023.
• The sharpest annual moves came in 2024 and 2026: EBT Margin jumped 12752 bps in 2024, then tumbled 445035 bps in 2026.
• A 4-year view of EBT Margin shows it stood at 22.08% in 2023, then plunged by 109 bps to 1.98% in 2024, then sank by 152116 bps to 3007.85% in 2025, then slumped by 51 bps to 4534.74% in 2026.
• The last three EBT Margin figures came in at 4534.74% (Q1 2026), 3007.85% (Q4 2025), and 2693.93% (Q3 2025), per Business Quant data.